This BTG2‐mediated p53 regulation leads to a switch from senescence to apoptosis, which reduces tumorigenicity in bladder cancer cells expressing oncogenic Ras and mutant p53 (O. R. Choi, Ryu, & Lim, 2016). Here, TP53 is linked to urinary bladder cancer.